Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 2 2 2012 12 30 Fluoxetine Improves the Effect of Levodopa on 6-Hydroxy Dopamine-Induced Motor Impairments in Rats 149 155 10.5681/apb.2012.023 EN Javad Mahmoudi Alireza Mohajjel Nayebi Siyamak Reyhani-Rad Morteza Samini Journal Article 10.5681/apb.2012.023 2012 05 14 Purpose: Long term L-DOPA therapy in Parkinson’s disease is associated with troublesome motor fluctuations such as L -DOPA Induced dyskinesia and wearing off effect. Our recent study showed that activation of 5-HT1A receptors could improve the anti-cataleptic effect of L-DOPA in parkinsonian rats. In this study we investigated the effect of fluoxetine on anti-parkinsonian effect of L-DOPA in 6-hydroxydopamine (6-OHDA)-lesioned rats. Methods: Catalepsy and motor incoordination were induced by unilateral injection of 6-OHDA (8µg/2µl/rat) into the central region of the sabstantia nigra pars compacta (SNc). After 3 weeks as a recovery period, these rats injected intraperitoneally (i.p.) L-DOPA (15 mg/kg) twice daily for 20 consecutive days, and anti-parkinsonian effect of L-DOPA was investigated by bar-test and rotarod on days 5, 10, 15 and 20. Results: The results showed that L-DOPA is able to improve motor coordination in rotarod only until day 15 and these effects of L-DOPA were abolished on the day 20. On day 21, rats were co-injected with fluoxetine (0.1, 0.5 and 1mg/kg, i.p.) and L-DOPA (15 mg/kg, i.p.). Fluoxetine increased anti-cataleptic effect of L-DOPA at the dose of 1 mg/kg, while fluoxetine had not any impact on the effect of L-DOPA in rotarod test. The effect of fluoxetine (1 mg/kg, i.p.) on anti-cataleptic effect of L-DOPA (15 mg/kg, i.p.) was reversed by 1-(2-methoxyphenyl)-4-(4-phthalimidobutyl) piperazine hydrobromide (NAN-190; 0.5 mg/kg, i.p.), as a 5-HT1A receptor antagonist. Conclusion: According to the results, it may be concluded that fluoxetine improves 6-OHDA-induced catalepsy and motor imbalance in L-DOPA- treated rats through activation of 5-HT1A. Further studies should be designed to clarify the precise mechanism of interaction between 5-HT1A and dopaminergic neurons.